<DOC>
	<DOC>NCT02756624</DOC>
	<brief_summary>This is study is evaluating the safety and tolerability of AC-170 Ophthalmic Solution</brief_summary>
	<brief_title>A Multi-Center, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution</brief_title>
	<detailed_description>Central Cornea Endothelial Cell Counts will be done on a subset of approximately 150 subjects to complete 100 subjects as part of the safety measures.</detailed_description>
	<mesh_term>Cetirizine</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>at least 2 years of age be able to selfadminister eye drops or have a parent/legal guardian available for this purpose if less than 18 years old have a history or family history of atopic disease (including allergic conjunctivitis) have ocular health within normal limits known contraindications or sensitivities to the study medication or its components any ocular condition that, in the opinion of the investigator, could affect the subjects safety trial parameters use of disallowed medication during the period indicated prior to the enrollment or during the study be pregnant, nursing, or planning a pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>